Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Bulletin from the Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ)

12 January 2021 – The Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ) was held on 12 January 2021 at the offices of Setterwalls Advokatbyrå at Sturegatan 10, Stockholm. Attendance at the meeting was solely possible via postal voting. The following resolutions were passed at the general meeting.Resolution to amend the articles of associationThe general meeting resolved, in accordance with the board of director’s proposal, to amend the Company’s articles of association with respect to, inter alia, prerequisites for participation at general meetings, the limits for

Alma Media issues positive profit warning following better than anticipated profitability development in Q4

Alma Media Corporation                                         Inside information 12 January 2021 at 1.20 p.m.ALMA MEDIA ISSUES POSITIVE PROFIT WARNING FOLLOWING BETTER THAN ANTICIPATED PROFITABILITY DEVELOPMENT IN Q4 Alma Media raises its guidance for the 2020 adjusted operating profit for continuing operations. The adjusted operating profit for Q4 2020 falls short of the level of the comparison period, while fall in profitability is less than anticipated in 2020. The company expects that the adjusted operating profit for 2020 will decline less than 10 per cent of the comparison

BioStock: Ultimovacs announces collaboration with AstraZeneca

Ultimovacs announced this morning that it will be participating in a phase II study in collaboration with AstraZeneca, along with the Nordic Society of Gynaecological Oncology (NSGO) and the European Network of Gynaecological Oncological Trial Groups (ENGOT). The aim of the randomized clinical trial is to evaluate Ultimovacs' proprietary universal cancer vaccine, UV1, in combination with AstraZeneca's durvalumab and olaparib in patients with relapsed ovarian cancer.Read the full article at biostock.se: https://www.biostock.se/en/ultimovacs-announces-collaboration-with-astrazeneca/

Strong preclinical immunization data for the ABNCoV2 cVLP-based COVID-19 vaccine published in Nature Communications

Today, ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces the publication of strong virus neutralization properties in animal proof-of-concept data for ABNCoV2, a unique capsid virus like particle (cVLP) based COVID-19 vaccine coated with ExpreS2-made SARS-CoV-2 antigens, in the esteemed scientific journal Nature Communications. The ABNCoV2 COVID-19 vaccine is the result of a strong collaboration effort by ExpreS2ion and its joint venture partner AdaptVac ApS (“AdaptVac”) together with the PREVENT-nCoV consortium, with an exclusive global

SimCorp A/S - Major shareholder announcement

With reference to Section 30 of Consolidated Act no. 377 of 2 April 2020 on capital markets, please be informed that SimCorp A/S January 12, 2021 was informed by The Capital Group Companies, Inc. that The Capital Group Companies, Inc. now owns 9.97% of the share capital and voting rights in SimCorp A/S. The shares are traded at NASDAQ Copenhagen A/S. Questions may be addressed to Anders Hjort, VP, Head of Investor Relations, SimCorp A/S (+45 3544 8800). SimCorp A/S

Changes in Preem's Executive Management Team

Preem today announces changes in the Executive Management Team.The management team will, from 18 January, consist of: Magnus Heimburg, Chief Executive Officer (CEO) Lina Stolpe, Chief Financial Officer (CFO) Peter Abrahamsson, Executive vice president (EVP) Sustainable Development Magnus Holm, Executive vice president (EVP) Supply & Trading Christian Bjerdén, Executive vice president (EVP) Market and Sales Ylva Nyberg, Executive vice president (EVP) Communications & Human Resources Aad van Bedaf, Executive vice president (EVP) Refining

Assemblin El strengthens its position in the Uppsala region, Sweden, with the acquisition of J&C El

Assemblin El has acquired the well-positioned electrical engineering company J.Östling & C.Sparf El AB (J&C El), operating in Uppsala region. J&C El has annual sales of approximately SEK 45 million and 28 employees.Since its founding in 2011, J&C El has developed into a strong and professional electrical engineering company with a loyal customer base. The customer mix contains a variety of property companies, industries, construction companies, municipalities, and private individuals with a high level of service. – Uppsala, Sweden’s fourth largest city, is a strategic location for us,

SAS Traffic figures - December 2020

Increased passenger numbers compared to November driven by holiday travelAlmost 400,000 passengers flew with SAS during December, an increase of 18% compared to last month, but a decline by 80% year over year. At the same time SAS reduced its capacity by 6% compared to November, which corresponds to a reduction of 74% compared to last year. The load factor came in at 33%, an increase of some 8 percentage units (p.u.) compared to the previous month, but down 38 p.u. compared to last year. The increase in passengers and load factor compared to November is mainly driven by an increased demand

BioStock: Interview with CombiGene's new CMC expert

The Swedish Gene Therapy Company CombiGene aims to complete its preclinical program for the epilepsy project CG01 this year, in order to begin studies in humans in 2022. In this transitional phase, CombiGene has accelerated its recruitment process to occupy several key positions. BioStock has spoken with the newly recruited CMC expert Martin Linhult who, with his long experience of bringing pharmaceuticals to the market, will primarily focus on the manufacturing process of CG01.Read the full interview with Martin Linhult at biostock.se:  https://www.biostock.se/en/interview-with-

KHK Capital secures £25m funding facility to support growth

Property bridging and development lender, KHK Capital, has secured a £25 million funding line fromUK savings and lending specialist, Shawbrook Bank.The new financing line enables KHK Capital to meet rapidly growing demand from new and repeat customers for lending solutions on a diverse range of residential and commercial property.   "KHK Capital has been a 'family office' working mostly with private funds for a number of years," said Andy Kent, founding partner of KHK Capital. "We are very pleased to have secured this financing through Shawbrook Bank at a time when we are

IFS to propel major transformation project for India’s largest defense manufacturer

Comprehensive ERP solution from IFS to be rolled out in collaboration with Tech Mahindra to 9,500 users, working at multiple divisions across IndiaLondon and Bangalore, January 12, 2021 – IFS , the global enterprise applications company, has signed a contract with Tech Mahindra , a leading provider of digital transformation, consulting and business reengineering services and solutions and the prime contractor for Hindustan Aeronautics Limited (HAL), to enable HAL ’s Project Parivartan Program, a US$ 54 million (

Swedbank Robur launches new policy and sharpens its strategies to opt out fossil fuels

Swedbank Robur's Policy for responsible investments has been updated and supplemented with three new strategies for exclude, include and engage, which will be applied to the company’s various fund types. Swedbank Robur's Climate Strategy was also revised during the year and sharpened further. In line with this, the fund company has per January 1[st], 2021, decided to expand its strategy to exclude fossil fuels to also encompass oil and gas in addition to coal¹.Swedbank Robur has updated its Policy for responsible investments by expanding its strategy for opting out of fossil fuels to

Q-Free: Share capital increase registered

Reference is made to stock exchange releases 5 January 2021, 6 January 2021 and 7 January 2021 related to conversion notices for the subordinated Convertible Bond Loan issued by Q-Free ASA 18 May 2020. The share capital increase has now been registered in the Norwegian Register of Business Enterprises. Q-Free ASA’s new share capital is NOK 40,913,083.80 divided into 107,666,010 shares with a par value of NOK 0.38 per share. Each share gives one vote at the Company’s general meeting. The new shares will be issued on a separate ISIN until a listing prospectus for the new shares has

IRLAB presents application of deep learning on multidimensional CNS drug efficacy data

IRLAB (Nasdaq Stockholm: IRLAB A) presents results from a collaboration between the Department of Mathematical Sciences at Chalmers University of Technology, Gothenburg, the specialist artificial intelligence (AI) company Smartr and IRLAB. Based on multidimensional in vivo phenotypic dose response profiles generated by IRLAB's ISP technology, it is found that in particular multilayer perceptron networks perform well for prediction of therapeutic indication and classification of drug candidates. The methodology further holds promise to discover new or expanded indications for both drug

NOTIFICATION OF MANAGERS’ AND CLOSELY RELATED PARTIES’ TRANSACTIONS WITH DAMPSKIBSSELSKABET NORDEN A/S’ SHARES IN CONNECTION WITH SHARE BUY-BACK PROGRAM

ANNOUNCEMENT NO. 9 - 12 JANUARY 2021 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcement no. 90/2020. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information: Martin Badsted, CFO, tel.: +45 3315 0451

Domainex invests in the Creoptix WAVEdelta to strengthen its fragment-based drug discovery platform

Wädenswil/Zurich, Switzerland, and Saffron Walden, UK, 12 January 2021 – Domainex Ltd. , a leading provider of integrated drug discovery services, is pleased to announce that it has invested in the WAVEdelta instrument from Creoptix AG . This instrument utilizes Grating-Coupled Interferometry  (GCI) to measure target binding on sensor chips, generating binding affinity and on/off rate kinetics in a high throughput manner. This system achieves superior

Invitation to presentation of Humana's report on fourth quarter and full year 2020

Humana's interim report for the fourth quarter and the full year 2020 results will be published at 08:00 CET on February 11, 2021. A web-cast telephone conference will be held at 09:00 CET the same day.The webcast, where CEO and President Rasmus Nerman and CFO Noora Jayasekara will present the report, will be accessible at Humana's website www.humanagroup.com. The presentation material will be published on the website before the conference starts. The webcast, and later the recorded version of the webcast, will also be available at www.financialhearings.com. To participate in the

Beactica Therapeutics and University of Dundee announce collaboration to develop WRN inhibitors to target cancer

Beactica Therapeutics AB, the Swedish drug discovery company, and University of Dundee, a top-ranked university in the UK for biological sciences, today announced a new research collaboration agreement. The two parties will work together in a project aimed at inhibiting WRN helicase, a protein with significant therapeutic potential for cancers with microsatellite instability. The collaboration will leverage core capabilities of each partner and build on the work of Professor John Rouse, on the control of chromosome stability and DNA repair in cancer. Beactica will contribute key

Gothenburg Green City Zone leads the way towards zero-emissions transportation in the near future

Currently in development, Gothenburg Green City Zone is a world first: an initiative by a number of major stakeholders including Volvo Cars to build a climate-neutral transportation system in a large geographical area of Gothenburg. New technology will be tested here to allow this part of Gothenburg to have 100% emission-free transport modes by 2030. And everyone is welcome to join in.Gothenburg and the Gothenburg region are growing, and the number of tourists and other visitors is set to double by 2030. This will bring a steady increase in demand for transportation, while at the same time

Lime Technologies CFO joins Itello Board of Directors

Stockholm, January 12, 2021 – Itello, a leading provider of Policy and Administration Systems and digital solutions for the life and pension insurance industry, has appointed Magnus Hansson to its Board of Directors. Magnus is currently Chief Financial Officer with the business software supplier Lime Technologies. He has previously held the CFO position at European House of Beds AB. Magnus has a Master’s degree from Jönköping International Business School. “Magnus is a welcome addition to our board, and he brings very relevant experience to Itello. We value his perspective on the B2B

Lime Technologies CFO joins Itello Board of Directors

Stockholm, January 12, 2021 – Itello, a leading provider of Policy and Administration Systems and digital solutions for the life and pension insurance industry, has appointed Magnus Hansson to its Board of Directors. Magnus is currently Chief Financial Officer with the business software supplier Lime Technologies. He has previously held the CFO position at European House of Beds AB. Magnus has a Master’s degree from Jönköping International Business School. “Magnus is a welcome addition to our board, and he brings very relevant experience to Itello. We value his perspective on the B2B

NCC to develop and build new headquarters for Genmab at Kontorværket in Copenhagen

The Kontorværket commercial area project developed by NCC occupies a central location in Valby, a district in central Copenhagen. Here, NCC will build Genmab’s new headquarters, which will meet high environmental standards for both the building and the area.[Illustration] Illustration: DISSING+WEITLINGGenmab A/S is a leader in the creation and development of differentiated antibody products for the treatment of cancer, with headquarters in Copenhagen, Denmark. The construction of Genmab’s new headquarters will start in April 2021 and is expected to be ready in the first quarter of 2023.

Finnair introduces one-way ticket fares for its flights within Europe

Finnair brings customers more choice and flexibility by introducing a new, one-way fare structure for its intra-Europe and domestic flights from 12 January 2021. One-way tickets with competitive fares are now available for all Finnair intra-Europe and domestic flights in all purchase channels.  “We want to offer our customers more choice and flexibility, and removing the complexity of return fare rules makes buying simpler and more transparent. Now the best fare levels will be available for all customers regardless of the length of stay in the destination. This is something our customers

The Nomination Committee’s proposal for Chair of the Board

In advance of the Nordic Entertainment Group AB (publ) (“NENT Group”) Annual General Meeting of shareholders to be held on Wednesday 19 May 2021, NENT Group Chair David Chance has decided not to stand for re-election. The NENT Group Nomination Committee proposes the election of Pernille Erenbjerg as the new Chair of the Board. Pernille Erenbjerg has served as member of the NENT Group Board since May 2020, and was previously President and CEO of TDC, a leading provider of integrated communications and entertainment solutions in Denmark and Norway. Pernille is currently Deputy Chair of

There are no items matching the current filter
There are no more items matching the current filter
Back to top